Company intelligence / Profile preview
Combined Therapeutics
Boston, Massachusetts, United Statescombinedtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has demonstrated preclinical proof-of-concept for its MOPCTx platform, showing the ability to target antigen expression to specific tissues while protecting vital organs. Collaborative research with Boston Children’s Hospital and Harvard Medical School supports the technology’s potential. No human clinical results reported as of May 2025.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA therapeuticsmRNA vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Boston Children’s HospitalHarvard Medical School (academic collaborations/partnerships)
Beyond the preview
Go deeper on Combined Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Combined Therapeutics.